Cargando…

Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study

OBJECTIVE: The purpose of this study was to investigate outcomes of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) comparing the different approaches used in Germany and Japan. METHODS: This binational IRB-approved retrospective dual-center study included a total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Auer, Timo A, Sofue, Keitaro, Ueshima, Eisuke, Rauer, Nina, Yamaguchi, Takeru, Gebauer, Bernhard, Hamm, Bernd, Murakami, Takamichi, Althoff, Christian E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355341/
https://www.ncbi.nlm.nih.gov/pubmed/35937908
http://dx.doi.org/10.2147/JHC.S359705
_version_ 1784763273269215232
author Auer, Timo A
Sofue, Keitaro
Ueshima, Eisuke
Rauer, Nina
Yamaguchi, Takeru
Gebauer, Bernhard
Hamm, Bernd
Murakami, Takamichi
Althoff, Christian E
author_facet Auer, Timo A
Sofue, Keitaro
Ueshima, Eisuke
Rauer, Nina
Yamaguchi, Takeru
Gebauer, Bernhard
Hamm, Bernd
Murakami, Takamichi
Althoff, Christian E
author_sort Auer, Timo A
collection PubMed
description OBJECTIVE: The purpose of this study was to investigate outcomes of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) comparing the different approaches used in Germany and Japan. METHODS: This binational IRB-approved retrospective dual-center study included a total of 94 HCC patients subdivided in a German and a Japanese cohort. For each patient, liver and tumor volumetry was performed using computed tomography (CT) and magnetic resonance imaging (MRI). Furthermore, a comprehensive risk profile, including body constitution and liver and kidney function was established. Primary endpoints were progression-free and overall survival (PFS/OS). RESULTS: PFS in the German cohort was 168 vs 224d in the Japanese cohort (p=0.640). When subdivided by BCLC stage, no significant differences were reported (p=0.160–0.429). OS was significantly longer in the Japanese cohort with 856 vs. 303d (p<0.001). OS for BCLC A was significantly longer in the Japanese cohort (1960 vs. 428d; p<0.001), while survival rates did not differ significantly in BCLC B (785 vs 330d; p=0.067) and C-stages (208 vs 302d; p=0.186). Older age (p=0.034), poorer liver/kidney function (p=0.025-0-035), and a higher liver/tumor ratio (p<0.001) were found to correlate with shorter survival. ECOG scores were significantly higher in the German cohort (p=0.002). CONCLUSION: While OS is longer in TACE-treated patients in the Japanese cohort compared to the German cohort, the two approaches seem to be equally effective as PFS does not differ significantly. The different survival rates may be caused by the different clinical performance status of the selected collectives. In very early and early stage HCC, TACE in Japan seems to be an effective treatment option while in Germany for patients in those stages TACE remains a second-line option for patients not available for surgery or ablation.
format Online
Article
Text
id pubmed-9355341
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93553412022-08-06 Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study Auer, Timo A Sofue, Keitaro Ueshima, Eisuke Rauer, Nina Yamaguchi, Takeru Gebauer, Bernhard Hamm, Bernd Murakami, Takamichi Althoff, Christian E J Hepatocell Carcinoma Original Research OBJECTIVE: The purpose of this study was to investigate outcomes of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) comparing the different approaches used in Germany and Japan. METHODS: This binational IRB-approved retrospective dual-center study included a total of 94 HCC patients subdivided in a German and a Japanese cohort. For each patient, liver and tumor volumetry was performed using computed tomography (CT) and magnetic resonance imaging (MRI). Furthermore, a comprehensive risk profile, including body constitution and liver and kidney function was established. Primary endpoints were progression-free and overall survival (PFS/OS). RESULTS: PFS in the German cohort was 168 vs 224d in the Japanese cohort (p=0.640). When subdivided by BCLC stage, no significant differences were reported (p=0.160–0.429). OS was significantly longer in the Japanese cohort with 856 vs. 303d (p<0.001). OS for BCLC A was significantly longer in the Japanese cohort (1960 vs. 428d; p<0.001), while survival rates did not differ significantly in BCLC B (785 vs 330d; p=0.067) and C-stages (208 vs 302d; p=0.186). Older age (p=0.034), poorer liver/kidney function (p=0.025-0-035), and a higher liver/tumor ratio (p<0.001) were found to correlate with shorter survival. ECOG scores were significantly higher in the German cohort (p=0.002). CONCLUSION: While OS is longer in TACE-treated patients in the Japanese cohort compared to the German cohort, the two approaches seem to be equally effective as PFS does not differ significantly. The different survival rates may be caused by the different clinical performance status of the selected collectives. In very early and early stage HCC, TACE in Japan seems to be an effective treatment option while in Germany for patients in those stages TACE remains a second-line option for patients not available for surgery or ablation. Dove 2022-08-01 /pmc/articles/PMC9355341/ /pubmed/35937908 http://dx.doi.org/10.2147/JHC.S359705 Text en © 2022 Auer et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Auer, Timo A
Sofue, Keitaro
Ueshima, Eisuke
Rauer, Nina
Yamaguchi, Takeru
Gebauer, Bernhard
Hamm, Bernd
Murakami, Takamichi
Althoff, Christian E
Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study
title Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study
title_full Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study
title_fullStr Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study
title_full_unstemmed Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study
title_short Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study
title_sort transarterial chemoebolization in hepatocellular carcinoma: a binational japanese-german study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355341/
https://www.ncbi.nlm.nih.gov/pubmed/35937908
http://dx.doi.org/10.2147/JHC.S359705
work_keys_str_mv AT auertimoa transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT sofuekeitaro transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT ueshimaeisuke transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT rauernina transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT yamaguchitakeru transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT gebauerbernhard transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT hammbernd transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT murakamitakamichi transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy
AT althoffchristiane transarterialchemoebolizationinhepatocellularcarcinomaabinationaljapanesegermanstudy